专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09085621B2 Anti-IL-1β antibodies 有权
标题翻译：抗IL-1和bgr 抗体
公开(公告)号：US09085621B2
公开(公告)日：2015-07-21
申请号：US13821942
申请日：2011-09-09
申请人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang
发明人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang
IPC分类号： C07K16/24 , A61K39/395 , A61K39/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/245 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-IL-1β monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.
摘要翻译：本发明提供抗IL-1和bgr。单克隆抗体和相关组合物，其可用于治疗炎性和其它疾病的各种治疗方法中的任何一种。

2. 发明申请

US20140322239A1 ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE 有权
标题翻译：抗IL-6受体抗体及其使用方法
公开(公告)号：US20140322239A1
公开(公告)日：2014-10-30
申请号：US14268932
申请日：2014-05-02
申请人： Sum Wai Pierre Lee , Yaohuang Ke , Yongke Zhang
发明人： Sum Wai Pierre Lee , Yaohuang Ke , Yongke Zhang
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
摘要翻译：本发明提供抗IL-6R单克隆抗体和相关组合物，其可用于治疗类风湿性关节炎和其它疾病的各种治疗方法中的任何一种。

3. 发明授权

US08753634B2 Anti-IL-6 receptor antibodies and methods of use 有权
标题翻译：抗IL-6受体抗体及其使用方法
公开(公告)号：US08753634B2
公开(公告)日：2014-06-17
申请号：US13407293
申请日：2012-02-28
申请人： Sum Wai Pierre Lee , Yaohuang Ke , Yongke Zhang
发明人： Sum Wai Pierre Lee , Yaohuang Ke , Yongke Zhang
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
摘要翻译：本发明提供抗IL-6R单克隆抗体和相关组合物，其可用于治疗类风湿性关节炎和其它疾病的各种治疗方法中的任何一种。

4. 发明申请

US20120225060A1 ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE 有权
标题翻译：抗IL-6受体抗体及其使用方法
公开(公告)号：US20120225060A1
公开(公告)日：2012-09-06
申请号：US13407293
申请日：2012-02-28
申请人： Sum Wai Pierre Lee , Yaohuang Ke , Yongke Zhang
发明人： Sum Wai Pierre Lee , Yaohuang Ke , Yongke Zhang
IPC分类号： C07K16/24 , A61P37/02 , A61P35/04 , C12N15/13 , A61K39/395
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
摘要翻译：本发明提供抗IL-6R单克隆抗体和相关组合物，其可用于治疗类风湿性关节炎和其它疾病的各种治疗方法中的任何一种。

5. 发明授权

US09441042B2 Anti-KDR antibodies and methods of use 有权
标题翻译：抗KDR抗体及其使用方法
公开(公告)号：US09441042B2
公开(公告)日：2016-09-13
申请号：US14356120
申请日：2012-11-01
申请人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang , Guo-Liang Yu , Weimin Zhu
发明人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang , Guo-Liang Yu , Weimin Zhu
IPC分类号： C07K16/28 , C07K14/71 , A61K39/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/71 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
摘要翻译：本发明提供抗KDR单克隆抗体和相关组合物，其可用于治疗各种癌症，类风湿性关节炎，糖尿病性视网膜病变和与异常VEGF或KDR表达相关的其它疾病的各种治疗方法中的任何一种， /或活动。

6. 发明申请

US20140377282A1 ANTI-KDR ANTIBODIES AND METHODS OF USE 有权
标题翻译：抗KDR抗体和使用方法
公开(公告)号：US20140377282A1
公开(公告)日：2014-12-25
申请号：US14356120
申请日：2012-11-01
申请人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang , Guo-Liang Yu , Weimin Zhu
发明人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang , Guo-Liang Yu , Weimin Zhu
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/71 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
摘要翻译：本发明提供抗KDR单克隆抗体和相关组合物，其可用于治疗各种癌症，类风湿性关节炎，糖尿病性视网膜病变和与异常VEGF或KDR表达相关的其它疾病的各种治疗方法中的任何一种， /或活动。

7. 发明申请

US20130330355A1 ANTI-IL-1BETA ANTIBODIES AND METHODS OF USE 有权
标题翻译：抗IL-1BETA抗体和使用方法
公开(公告)号：US20130330355A1
公开(公告)日：2013-12-12
申请号：US13821942
申请日：2011-09-09
申请人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang
发明人： Yaohuang Ke , Sum Wai Pierre Lee , Yongke Zhang
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/245 , C07K2317/24 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-IL-1β monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.
摘要翻译：本发明提供抗IL-1beta单克隆抗体和相关组合物，其可用于治疗炎症和其它疾病的各种治疗方法中的任何一种。

8. 发明授权

US08986692B2 Anti-VEGF monoclonal antibody and pharmaceutical composition comprising said antibody 有权
标题翻译：抗VEGF单克隆抗体和包含所述抗体的药物组合物
公开(公告)号：US08986692B2
公开(公告)日：2015-03-24
申请号：US13393185
申请日：2010-08-27
申请人： Pierre Li , Yaohuang Ke , Yongke Zhang , Weimin Zhu , Guoliang Yu , Fanxin Ma , Xin Fan
发明人： Pierre Li , Yaohuang Ke , Yongke Zhang , Weimin Zhu , Guoliang Yu , Fanxin Ma , Xin Fan
IPC分类号： A61K39/395 , C07K16/22 , A61K39/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.
摘要翻译：本发明提供了抗VEGF单克隆抗体，其具有包含SEQ ID NO：1，SEQ ID NO：2和SEQ ID NO：3的氨基酸序列的重链可变区和/或轻链，其包含SEQ ID NO：4，SEQ ID NO：5和SEQ ID NO：6的氨基酸序列。该抗体可以通过具有CGMCC NO保存数的细胞系产生。本发明还提供了所述抗体用于制备用于治疗与VEGF相关的疾病的药物的用途，其中还提供了包含所述抗体的药物组合物，试剂，试剂盒和切片以及细胞系保存号码为CGMCC NO。 3233。

9. 发明申请

US20120231011A1 ANTI-VEGF MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY 有权
标题翻译：抗VEGF单克隆抗体和包含抗体的药物组合物
公开(公告)号：US20120231011A1
公开(公告)日：2012-09-13
申请号：US13393185
申请日：2010-08-27
申请人： Pierre Li , Yaohuang ke , Yongke Zhang , Weimin Zhu , Guoliang Yu , Fanxin Ma , Xin Fan
发明人： Pierre Li , Yaohuang ke , Yongke Zhang , Weimin Zhu , Guoliang Yu , Fanxin Ma , Xin Fan
IPC分类号： C07K16/22 , A61K39/395 , A61P3/10 , A61P25/28 , A61P3/04 , C12N5/07 , A61P25/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.
摘要翻译：本发明提供了一种抗VEGF单克隆抗体，其具有包含SEQ ID NO：1的氨基酸序列的重链可变区。 1，SEQ ID NO： 2和SEQ ID NO。 3，和/或包含SEQ ID NO：1的氨基酸序列的轻链的可变区。 4，SEQ ID NO： 5和SEQ ID NO：抗体可以通过具有CGMCC NO保存数的细胞系产生。本发明还提供了所述抗体用于制备用于治疗与VEGF相关的疾病的药物的用途，其中还提供了包含所述抗体的药物组合物，试剂，试剂盒和切片以及细胞系保存号码为CGMCC NO。 3233。

10. 发明申请

US20130089540A1 New Humanized Anti-CD20 Monoclonal Antibody 有权
标题翻译：新型人源化抗CD20单克隆抗体
公开(公告)号：US20130089540A1
公开(公告)日：2013-04-11
申请号：US13634072
申请日：2011-03-16
申请人： Jie Liu , Yongke Zhang
发明人： Jie Liu , Yongke Zhang
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2317/734
摘要： The present invention discloses methods of design and preparation for a new humanized anti-CD20 monoclonal antibody, related genes, protein sequence, and the use of said antibody. Comparing to murine-derived antibodies and human-mouse chimeric antibodies, said humanized anti-CD20 antibody maintains or improves high binding activity of the variable regions, meanwhile reduces the immunogenicity of chimeric antibodies, consequently achieves the effect of reducing medicine side effects and improving clinical treatment. The antibody disclosed by the present invention is efficiently expressed in animal cells, can be used for industrial production. It could be used in treating B cell lymphoma, leukaemia, or B cell-associated autoimmune disease with a wide application prospect.
摘要翻译：本发明公开了新的人源化抗CD20单克隆抗体，相关基因，蛋白质序列以及所述抗体的应用的设计和制备方法。与鼠源抗体和人 - 小鼠嵌合抗体相比，所述人源化抗CD20抗体维持或提高可变区的高结合活性，同时降低嵌合抗体的免疫原性，从而达到降低药物副作用和改善临床效果治疗。本发明公开的抗体在动物细胞中有效表达，可用于工业生产。可用于治疗B细胞淋巴瘤，白血病或B细胞相关自身免疫性疾病，应用前景广阔。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式